the development of biologically active medication to treat tbc patients
DESCRIPTION
The development of biologically active medication to treat TBC patients. Malkov S . А., Shironosov O . V ., Shironosova G . I. PROBLEM TOPICALITY. Every year TBC causes the following : 1 billon people infection ; 8-10 billion people illness ; - PowerPoint PPT PresentationTRANSCRIPT
The development of biologically active medication to treat TBC patients
Malkov S. А., Shironosov O.V., Shironosova G.I.
PROBLEM TOPICALITY
Every year TBC causes the following:
1 billon people
infection; 8-10 billion people
illness; 3-4 billion people death.
WHO declared TBC the global danger in 1993.
Is expensive (the average cost of one bed day - 1600 rubles);
Causes poisonous effect; Requires long-term (4-6
months) administration; Is aggravated by
multidrug resistance.
Modern TBC patient treatment
Galleria Mellonella – The Greater Wax Moth
I.I. Mechnikov (1889); S.А. Mukhin (1955); N.А. Spiridonov (1989).
Extract's properties:1. Immune protective;2. Antimicrobial;3. Antioxidant.
HOW TO GET A BIOACTIVE PRODUCT FROM THE GREATER WAX MOTH LARVAE(21)4938002/14 (22) 2603.91 (46)2706.95 Bulletin №18 (71) Institute of Theoretical and Experimental Biophysics, USSR Academy of Sciences(72) Spiridonov NA; Rachkov AK; Mukhin SA; Kondrashova MN. (73) Spiridonov Nikolay Aleksandrovich(55) USSR certificate of authorship N 1284229, 61 35/04. 1989. А К
The way of noncontact activation
Solutions with negative redox potential
THE PROJET’S AIM
is the development of bioactive medication (with long-lasting redox potential) on the basis of water solutions of The Greater Wax Moth larvae to treat TBC patients.
DYNAMICS OF REDOX POTENTIAL CHANGE
Date 09.07.11 12.08.11 18.08.11 24.08.11 06.09.11
Control (redox potential , mV)
80 84 82 79 83
Experiment (redox potential , mV)
-193 -248 -301 -445 -476
Clinical research
Republican tuberculosis dispensary:
15 patients; Infiltrative TB. Average age - 40 years; Gender - male; Treatment duration – 3,5
months.
Research results
twofold reduction of abacillary duration;reduction of intoxication;improvement of blood value (reduction of the number of lymphocytes, improvement of differential blood cell count, ESR reduction, etc.).
Commercialization perspectives
Bed day shortening by 1,5-2 times.
Treatment course depreciation.
Increase of medication’s biological activity .
Demand assessment after launching
Demand assessment after launching:
1st year (USD) 3rd year (USD)
Russia 50 000 200 000
CIS countries 70 000 300 000
ЕС countries, USA 100 000 350 000
GRNT - GLOBAL RESONANCE NONLINEAR TECHNOLOGIES
Thank You
and
Be Healthy!
http://grnt.biz